-
Categories
-
Pharmaceutical Intermediates
-
Active Pharmaceutical Ingredients
-
Food Additives
- Industrial Coatings
- Agrochemicals
- Dyes and Pigments
- Surfactant
- Flavors and Fragrances
- Chemical Reagents
- Catalyst and Auxiliary
- Natural Products
- Inorganic Chemistry
-
Organic Chemistry
-
Biochemical Engineering
- Analytical Chemistry
- Cosmetic Ingredient
-
Pharmaceutical Intermediates
Promotion
ECHEMI Mall
Wholesale
Weekly Price
Exhibition
News
-
Trade Service
According to statistics, there are 75.
According to statistics, there are 75.
Safe and effective vaccines are essential to eliminate HIV (HIV) infection.
P5 subsequently developed a similar program, using HIV-1 subtype C sub-Saharan African strains, followed by injection of recombinant canine pox vector containing subtype C envelope ALVAC-HIV (vCP2438) and MF59-assisted C subtype double Glycoprotein 120 (gp120) vaccine.
In the previous phase 1-2a trial, it was found that this vaccine regimen was safe and could induce a strong humoral and cellular immune response.
In the previous phase 1-2a trial, it was found that this vaccine regimen was safe and could induce a strong humoral and cellular immune response.
To this end, in the International HIV Vaccine Trial Network (HVTN) 702 trial, researchers investigated the safety and effectiveness of this vaccine program to obtain HIV-1 in South Africa.
The vaccine regimen includes ALVAC-HIV injections at 0 and 1 months, followed by 4 injections of ALVAC-HIV at 3, 6, 12, and 18 months plus the bivalent type C gp120-MF59 adjuvant.
In general, in the interim analysis in January 2020, the pre-specified non-efficacy standard was reached; for this reason, the research organization subsequently stopped further vaccination.
In general, in the interim analysis in January 2020, the pre-specified non-effect standard was reached; in general, the interim analysis in January 2020 met the pre-specified non-effect standard;
In the second analysis during the 36-month follow-up period, the incidence of HIV-1 infection in the vaccine group and the placebo group was similar (OR=1.
In the secondary analysis during the 36-month follow-up period, the incidence of HIV-1 infection in the vaccine group and the placebo group was similar (OR=1.
Further analysis showed that between randomization and the 24th month, the efficacy of the vaccines based on gender was similar between the two groups.
Further analysis showed that between randomization and the 24th month, the efficacy of the vaccines based on gender was similar between the two groups.
In summary, despite previous evidence of immunogenicity, ALVAC-gp120 therapy did not prevent South African participants from being infected with HIV-1.
references:
Vaccine Efficacy of ALVAC-HIV and Bivalent Subtype C gp120–MF59 in Adults.
Vaccine Efficacy of ALVAC-HIV and Bivalent Subtype C gp120–MF59 in Adults.
Leave a message here
